Price$3.15+0.03 (+0.96%)
03:15 PM07:45 PM
News · 26 weeks36+233%
2025-10-262026-04-19
Mix1590d
- Market7(47%)
- SEC Filings4(27%)
- Analyst2(13%)
- Other2(13%)
Latest news
25 items- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Announces Chief Financial Officer TransitionPaul Hitchin to step down as of April 30, 2026Claire Hinshelwood appointed to CFO role as of May 1, 2026 HAMBURG, DE / ACCESS Newswire / April 24, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that Chief Financial Officer (CFO) Paul Hitchin will step down on April 30, 2026, for personal reasons unrelated to the company. The Supervisory Board has accepted Mr. Hitchin's decision and expressed deep appreciation for his leadership and significant contributions to the company. Since March 1, 2025, he successfully led Evotec through a significant financial and strategic evolution.Mr. Hitchin will be succeeded by Claire Hinshelwood, effective May 1, 2026. Ms. Hinshelwo
- ANALYSTH.C. Wainwright resumed coverage on Evotec SE with a new price targetH.C. Wainwright resumed coverage of Evotec SE with a rating of Buy and set a new price target of $7.00
- NEWSEvotec Appoints Dr. Ingrid Müller as Chief Operating OfficerWill play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiativeBrings more than 20 years of international leadership experience across operations, transformation, strategy, supply, procurement and R&D integrationHAMBURG, DE / ACCESS Newswire / April 15, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ingrid Müller as Chief Operating Officer (COO). Dr. Müller will be joining Evotec's Management Board, effective May 1, 2026. She brings to Evotec more than 20 years of international leadership experience in the life scien
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECSEC Form 20-F filed by Evotec SE20-F - Evotec SE (0001412558) (Filer)
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Nominates Dieter Weinand as Supervisory Board ChairmanStrengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitabilityIndustry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, commercial, operational and strategic rolesHAMBURG, DE / ACCESS Newswire / April 7, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that the Supervisory Board of Evotec SE has proposed the election of Dieter Weinand, M.S. as Chairman of the Supervisory Board at the June 11, 2026, Annual General Meeting. The nomination reflects Evotec's continued commitment to strengthening commercial execu
- NEWSEvotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and provide a business update on Wednesday, April 8, 2026. The conference call will be held in English.Webcast detailsDate: Wednesday, April 8, 2026Time: 2.00 pm CEST (12.00 pm GMT, 8.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com.Conference call detailsTo join the conference call, please pre-register via this link. You will then receive
- NEWSEvotec Appoints Dr. Ashiq H. Khan as Chief Commercial OfficerHAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. Dr. Khan brings to Evotec over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, with a distinguished track record of managing diverse transcontinental teams and closing more than $7 billion in high-value standalone, integrated, and collaboration agreements across the U.S., EU and APAC markets. In his role, Dr. Khan will spearhead the build-out of a globally integrated, fit-for-purpose commercial organization fully aligned with Evotec's scientific
- NEWSJust - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related VirusesThe program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yieldsManufacturing process development strengthens U.S. government response capabilities against hemorrhagic fever outbreaks caused by Ebola and Sudan virusHAMBURG, DE / ACCESS Newswire / March 23, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced its Seattle-based subsidiary and CDMO, Just - Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufact
- NEWSEvotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study InitiationDosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear cell renal cell carcinomaStudy start highlights transition into the clinic for Evotec-BMS oncology platform and reflects robust pipeline of 'molecular glues' being advanced as treatment options for different cancer typesValidates Evotec's high-performance multi-omics screening and AI-supported data analytics and drug design capabilitiesHAMBURG, DE / ACCESS New
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Evotec SESCHEDULE 13G/A - Evotec SE (0001412558) (Subject)
- ANALYSTBerenberg initiated coverage on Evotec SEBerenberg initiated coverage of Evotec SE with a rating of Buy
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSJust - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable AccessJust - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalitiesInvestment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the next three yearsHAMBURG, DE / ACCESS Newswire / January 8, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announces that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just - Evotec Biologics' molecular design suite of computational technologies, called "J.MD™".Investment (INV07213
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor RelationsCreation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignmentHAMBURG, DE / ACCESS Newswire / January 2, 2026 / Evotec SE (NASDAQ:EVO, Frankfurt Prime Standard:EVT)) today announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this strategic role, Dr. Fakih will lead Evotec's newly integrated Global Communications and Investor Relations function.Reporting directly to CEO Dr. Christian Wojczewski, she will bring together both teams to strengthen alignment, clarity and engagement across stakeholders. The integration of C
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Closes Sale of Just - Evotec Biologics' Toulouse Site to SandozAll closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec's continuous manufacturing platformIn addition, Evotec eligible for license fees, and development revenues including success-based milestones adding up to more than US$ 300 m over the coming years,replacing existing contractual commitmentsTransaction covering royalties on a portfolio ofup to ten biosimilars in technical and early development targetingmore than US$ 90 bn of originator net salesSale imme